Hereditary Genetic Testing Market Report 2026
Global Outlook – By Type (Predictive And Presymptomatic Testing, Carrier Testing, Prenatal And Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Other Types), By Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing), By Clinical Application (Cancer Genetic Testing, Cardiovascular Genetic Testing, Neurological Genetic Testing, Rare Diseases Genetic Testing), By End User (Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Direct To Consumer (DTC) Genetic Testing Companies) – Market Size, Trends, Strategies, and Forecast to 2030
Hereditary Genetic Testing Market Overview
• Hereditary Genetic Testing market size has reached to $23.88 billion in 2025 • Expected to grow to $40.12 billion in 2030 at a compound annual growth rate (CAGR) of 10.9% • Growth Driver: Growing Cancer Incidence Spurs Expansion Of Genetic Testing Services • Market Trend: Advancements In Genomic Solutions Enhance Early Cancer Detection And Treatment • North America was the largest region and fastest growing region.What Is Covered Under Hereditary Genetic Testing Market?
Hereditary genetic testing is a medical test that examines deoxyribonucleic acid (DNA) to identify inherited gene mutations that may cause disease. It helps determine an individual's risk of developing certain genetic conditions passed down from parents to children. This testing is often used for conditions such as cancer, heart disease, and rare inherited disorders. The main types of hereditary genetic testing are predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and others. Predictive and presymptomatic testing identifies individuals with a genetic predisposition to develop certain diseases before symptoms appear. The various technologies include cytogenetic testing, biochemical testing, and molecular testing. Clinical applications of hereditary genetic testing cover cancer genetic testing, cardiovascular genetic testing, neurological genetic testing, and rare diseases genetic testing. The end users are hospitals and clinics, diagnostic laboratories, research institutes, and direct-to-consumer (DTC) genetic testing companies.
What Is The Hereditary Genetic Testing Market Size and Share 2026?
The hereditary genetic testing market size has grown rapidly in recent years. It will grow from $23.88 billion in 2025 to $26.56 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing prevalence of hereditary disorders, growing clinical adoption of molecular diagnostics, expansion of diagnostic laboratories, rising awareness of genetic diseases, availability of basic genetic testing technologies.What Is The Hereditary Genetic Testing Market Growth Forecast?
The hereditary genetic testing market size is expected to see rapid growth in the next few years. It will grow to $40.12 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to advancements in next-generation sequencing technologies, growing demand for personalized medicine, expansion of pharmacogenomic applications, increasing healthcare spending on preventive care, wider integration of genetic counseling services. Major trends in the forecast period include rising adoption of preventive and predictive genetic testing, increasing demand for early cancer risk assessment, growth of direct-to-consumer genetic testing services, expansion of prenatal and newborn genetic screening, rising awareness of inherited cardiovascular and rare diseases.
Global Hereditary Genetic Testing Market Segmentation
1) By Type: Predictive And Presymptomatic Testing, Carrier Testing, Prenatal And Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Other Types 2) By Technology: Cytogenetic Testing, Biochemical Testing, Molecular Testing 3) By Clinical Application: Cancer Genetic Testing, Cardiovascular Genetic Testing, Neurological Genetic Testing, Rare Diseases Genetic Testing 4) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Direct To Consumer (DTC) Genetic Testing Companies Subsegments: 1) By Predictive And Presymptomatic Testing: Genetic Testing For Disease Risk Prediction, Testing For Inherited Cancer Risks, Cardiovascular Disease Risk Testing, Neurodegenerative Disease Risk Testing 2) By Carrier Testing: Testing For Inherited Genetic Disorders, Genetic Screening For Autosomal Recessive Diseases, Testing For Carrier Status Of Inherited Conditions 3) By Prenatal and Newborn Testing: Non-Invasive Prenatal Testing (NIPT), Amniocentesis and Chorionic Villus Sampling (CVS), Newborn Screening For Genetic Disorders, Preconception Genetic Screening 4) By Diagnostic Testing: Genetic Testing For Confirming Suspected Genetic Disorders, Testing For Inherited Syndromes And Congenital Diseases, Diagnostic Testing For Cancer And Tumor Profiling 5) By Pharmacogenomic Testing: Genetic Testing For Drug Response And Efficacy, Testing For Drug Sensitivities And Side Effects, Personalized Medicine And Treatment Optimization 6) By Other Types: Genetic Testing For Wellness And Lifestyle, Genetic Testing For Ancestry And Genealogy, Research-Oriented Genetic TestingWhat Is The Driver Of The Hereditary Genetic Testing Market?
The increasing prevalence of cancer is expected to propel the growth of the hereditary genetic testing market going forward. Cancer refers to a collection of diseases marked by abnormal cell growth that can invade or spread to other parts of the body. The increasing prevalence of cancer can be attributed to factors such as aging populations, lifestyle changes, environmental pollutants, genetic predispositions, and improved diagnostic techniques. Hereditary genetic testing helps prevent cancer by identifying genetic mutations associated with increased risk, enabling early surveillance and targeted prevention strategies. For instance, in August 2024, according to the Macmillan Cancer Support, a UK-based organization, reported that in 2024, more than 3 million people in the UK are living with cancer, this figure is projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing prevalence of cancer is driving the growth of the hereditary genetic testing industry.Key Players In The Global Hereditary Genetic Testing Market
Major companies operating in the hereditary genetic testing market are F. Hoffmann‑La Roche Ltd., Abbott Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Hologic Inc., Exact Sciences Corporation, Fulgent Genetics Inc., BioReference Laboratories Inc., BGI Group, Invitae Corporation, Color Health Inc., MedGenome Inc., Devyser AB, Mapmygenome India Ltd., Igenomix S.L.P., Myriad Genetics Inc., Natera Inc., Ambry Genetics Corporation, GeneDx LLC, Centogene N.V., CooperSurgical Inc., Sema4
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Hereditary Genetic Testing Market Trends and Insights
Major companies operating in the hereditary genetic testing market are focused on developing advanced genomic solutions, such as multi-cancer multigene panels, to enhance early detection and personalized treatment options. Multi-cancer multigene panels are diagnostic tests that analyze multiple genes simultaneously to detect genetic mutations associated with various types of cancer, aiding in early diagnosis and personalized treatment. For instance, in February 2024, Exact Sciences Corporation, a US-based provider of cancer screening and diagnostic tests, launched the Riskguard hereditary cancer test. The Riskguard test delivers a personalized report on gene-specific and familial cancer risks using a simple blood or saliva sample for 10 common cancers. It aids in understanding cancer risk, informing screening and treatment plans, and assessing family risks. Additionally, it helps tailor treatment for patients already diagnosed with cancer and enhances risk stratification for those with a family history of cancer by identifying actionable gene variants.What Are Latest Mergers And Acquisitions In The Hereditary Genetic Testing Market?
In August 2024, Laboratory Corporation of America Holdings (Labcorp), a US-based laboratory services providing company, acquired select assets of Invitae Corporation for an undisclosed amount. With this acquisition, it aims to expand its specialty testing capabilities and enhance its use of genetic data to improve clinical trials and treatment regimens in oncology and select rare diseases. Invitae Corporation is a US-based provider of medical genetics services including genetic testing solutions for oncology and rare diseases.
Regional Outlook
North America was the largest region in the hereditary genetic testing market in 2025 and it is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, SpainNeed data for a specific geography? Request Regional Data
What Defines the Hereditary Genetic Testing Market?
The hereditary genetic testing market includes revenues earned by entities by providing services such as carrier screening, prenatal testing, and newborn screening. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Hereditary Genetic Testing Market Report 2026?
The hereditary genetic testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary genetic testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Hereditary Genetic Testing Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $26.56 billion |
| Revenue Forecast In 2030 | $40.12 billion |
| Growth Rate | CAGR of 10.9% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Type, Technology, Clinical Application, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | F. Hoffmann‑La Roche Ltd., Abbott Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Hologic Inc., Exact Sciences Corporation, Fulgent Genetics Inc., BioReference Laboratories Inc., BGI Group, Invitae Corporation, Color Health Inc., MedGenome Inc., Devyser AB, Mapmygenome India Ltd., Igenomix S.L.P., Myriad Genetics Inc., Natera Inc., Ambry Genetics Corporation, GeneDx LLC, Centogene N.V., CooperSurgical Inc., Sema4 |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |